Thrombophilic Status May Predict Prognosis in Patients With Metastatic BRAFV600-mutated Melanoma Who Are Receiving BRAF Inhibitors

Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2015.11.006
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Elsevier BV

Related search

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

Combining Checkpoint Inhibitors and BRAF-targeted Agents Against Metastatic Melanoma

OncoImmunology
OncologyAllergyImmunology
2013English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition

Oncotarget
Oncology
2017English

Uncommon BRAF Mutations Associated With Durable Response to Immunotherapy in Patients With Metastatic Melanoma

Case Reports in Oncological Medicine
Oncology
2017English

Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology
Cancer ResearchOncology
2018English

Detection of Mutant BRAF Alleles in the Plasma of Patients With Metastatic Melanoma

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2007English

Rechallenge With Checkpoint Inhibitors in Metastatic Melanoma

JDDG - Journal of the German Society of Dermatology
Dermatology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy